Amgen: Biotech Giant's Path to Growth and Recovery
Amgen has navigated headwinds to chart a path toward renewed growth. This analysis breaks down the catalysts, risks, ...
Index benchmarks provide a transparent yardstick for performance, helping investors gauge risk-adjusted returns and make informed choices.
27,627 articlesAmgen has navigated headwinds to chart a path toward renewed growth. This analysis breaks down the catalysts, risks, ...
A MeiraGTx insider recently sold shares as the biotech nears two pivotal drug filings. This article breaks down what ...
As AI expands, the backbone—data centers and compute—becomes a focal point for investors. This guide compares CoreWea...
Ford surprised markets with an upward revision to its 2026 guidance after a solid first quarter. This article breaks ...
As a new Fed chair, chair kevin warsh will confront two high-stakes tests in just 100 days. One test centers on polit...
A new Fed chair promises reform, but progress stalls. This article explains the investing implications when it's been...
The Trade Desk is signaling a broader pivot beyond its core DSP strengths. This article breaks down how trade desk re...
Intuitive Surgical has faced a sharp stock pullback this year. This article breaks down the factors behind the move, ...
Alphabet's plan to issue new stock could dilute existing holders. This deep dive explains what that means for investo...
A Fulton Financial director sold shares after the stock surged about 26%. This article breaks down what insider sales...
Meta Platforms stock has moved lower—about 17% over six months. This article breaks down what that decline means, how...
Ford stock raced 52-week highs this week as the company signals a bold shift toward AI-driven infrastructure. This ar...